- Home
- PRLD vs FSI Comparison
PRLD vs FSI Comparison
Compare PRLD & FSI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PRLD
- FSI
- Stock Information
- Founded
- PRLD 2016
- FSI 1991
- Country
- PRLD United States
- FSI Canada
- Employees
- PRLD N/A
- FSI N/A
- Industry
- PRLD Medicinal Chemicals and Botanical Products
- FSI Recreational Games/Products/Toys
- Sector
- PRLD Health Care
- FSI Consumer Discretionary
- Exchange
- PRLD Nasdaq
- FSI Nasdaq
- Market Cap
- PRLD 73.7M
- FSI N/A
- IPO Year
- PRLD 2020
- FSI 1999
- Fundamental
- Price
- PRLD $0.77
- FSI $5.14
- Analyst Decision
- PRLD Strong Buy
- FSI
- Analyst Count
- PRLD 2
- FSI 0
- Target Price
- PRLD $4.50
- FSI N/A
- AVG Volume (30 Days)
- PRLD 254.5K
- FSI 24.9K
- Earning Date
- PRLD 03-10-2025
- FSI 03-31-2025
- Dividend Yield
- PRLD N/A
- FSI 1.98%
- EPS Growth
- PRLD N/A
- FSI 9.09
- EPS
- PRLD N/A
- FSI 0.24
- Revenue
- PRLD $7,000,000.00
- FSI $38,234,860.00
- Revenue This Year
- PRLD N/A
- FSI $0.73
- Revenue Next Year
- PRLD N/A
- FSI $34.59
- P/E Ratio
- PRLD N/A
- FSI $21.04
- Revenue Growth
- PRLD N/A
- FSI N/A
- 52 Week Low
- PRLD $0.63
- FSI $1.65
- 52 Week High
- PRLD $6.80
- FSI $7.24
- Technical
- Relative Strength Index (RSI)
- PRLD 50.06
- FSI 41.57
- Support Level
- PRLD $0.71
- FSI $5.12
- Resistance Level
- PRLD $0.76
- FSI $5.65
- Average True Range (ATR)
- PRLD 0.07
- FSI 0.26
- MACD
- PRLD 0.02
- FSI -0.02
- Stochastic Oscillator
- PRLD 58.46
- FSI 13.10
About PRLD Prelude Therapeutics Incorporated
Prelude Therapeutics Incorp is a clinical-stage precision oncology company focused on discovering and developing small molecule therapies optimized to target the key driver mechanisms in cancers with high unmet needs. The company's pipeline includes four candidates currently in clinical development: PRT1419, a potent, selective inhibitor of MCL1; PRT2527, a potent and selective CDK9 inhibitor, PRT3645, a next-generation CDK4/6 inhibitor, and PRT3789 a first-in-class SMARCA2/BRM protein degrader.